Modality
Cell Therapy
MOA
Menini
Target
CD20
Pathway
Checkpoint
Pancreatic CaCSUCLL
Development Pipeline
Preclinical
Apr 2020
→ Jun 2029
PreclinicalCurrent
NCT03297603
2,458 pts·CSU
2023-08→2029-06·Terminated
NCT03549057
2,554 pts·Pancreatic Ca
2020-04→2026-04·Not yet recruiting
5,012 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-183w awayInterim· Pancreatic Ca
2029-06-033.2y awayInterim· CSU
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Preclinical
Not yet…
Preclinical
Termina…
Catalysts
Interim
2026-04-18 · 3w away
Pancreatic Ca
Interim
2029-06-03 · 3.2y away
CSU
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03297603 | Preclinical | CSU | Terminated | 2458 | Biomarker |
| NCT03549057 | Preclinical | Pancreatic Ca | Not yet recr... | 2554 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| AKR-4818 | Akero | Approved | CD20 |